Share on StockTwits

Repligen Corp. (NASDAQ:RGEN) SVP Daniel P. Witt purchased 10,000 shares of the stock on the open market in a transaction that occurred on Tuesday, April 15th. The stock was purchased at an average cost of $3.05 per share, with a total value of $30,500.00. Following the purchase, the senior vice president now directly owns 57,709 shares in the company, valued at approximately $176,012. The acquisition was disclosed in a filing with the SEC, which is available at this link.

Separately, analysts at Jefferies Group initiated coverage on shares of Repligen Corp. in a research note on Tuesday. They set a “buy” rating and a $17.00 price target on the stock.

Repligen Corp. (NASDAQ:RGEN) traded up 5.12% during mid-day trading on Tuesday, hitting $14.37. 858,427 shares of the company’s stock traded hands. Repligen Corp. has a one year low of $7.37 and a one year high of $17.26. The stock’s 50-day moving average is $14.43 and its 200-day moving average is $13.12. The company has a market cap of $458.9 million and a P/E ratio of 27.34.

Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, March 6th. The company reported $0.10 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.04. The company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $15.88 million. Repligen Corp.’s revenue was down 18.1% compared to the same quarter last year. On average, analysts predict that Repligen Corp. will post $0.24 earnings per share for the current fiscal year.

Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.